Zhongyuan Union Health (600645.SH) subsidiary VUM02 injection has obtained clinical trial approval.

Smart Financial News APP, Zhongyuan Xiehe (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., received the "Notice of Approval of Drug Clinical Trial for VUM02 Injection for the Treatment of Severe/Critical Pneumonia" issued by the National Medical Products Administration on September 9, 2025.